SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I
about
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I
description
im Oktober 2016 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 October 2016
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2016
@uk
name
SAKK 24/09: safety and tolerab ...... ulticenter, randomized phase I
@en
SAKK 24/09: safety and tolerab ...... ulticenter, randomized phase I
@nl
type
label
SAKK 24/09: safety and tolerab ...... ulticenter, randomized phase I
@en
SAKK 24/09: safety and tolerab ...... ulticenter, randomized phase I
@nl
prefLabel
SAKK 24/09: safety and tolerab ...... ulticenter, randomized phase I
@en
SAKK 24/09: safety and tolerab ...... ulticenter, randomized phase I
@nl
P2093
P50
P1433
P1476
SAKK 24/09: safety and tolerab ...... er, randomized phase III trial
@en
P2093
Andreas Müller
Andreas Trojan
Daniel Rauch
Daniela Bärtschi
Jürg Bernhard
Khalil Zaman
Kyung-Jae Na
Marcus Vetter
Markus Borner
P2888
P356
10.1186/S12885-016-2823-Y
P407
P577
2016-10-10T00:00:00Z
P6179
1012136749